Related Experiment Videos
Orthopedic aspects of skeletal dysplasia in children
1Department of Orthopedic Surgery, University of Iowa Hospitals and Clinics, Iowa City 52242-1088.
Insights
Recent advances in skeletal dysplasia management include revised classifications and new genetic insights. Emerging therapies show promise, but long-term effectiveness requires further study for conditions like osteogenesis imperfecta.
Area of Science:
- Orthopedics and Genetics
- Skeletal Dysplasia Research
Background:
- Significant progress has been made in understanding and managing skeletal dysplasias.
- Genetic heterogeneity within similar phenotypes is being uncovered through new mutation identification.
Purpose of the Study:
- To review recent advances in skeletal dysplasia management.
- To highlight new findings in classification, genetics, and treatment of bone disorders.
Main Methods:
- Review of recent clinical data and pilot studies.
- Analysis of proposed revisions to the Paris classification of constitutional bone disorders.
- Investigation of genetic heterogeneity in skeletal dysplasias.
Main Results:
- New mutations identified confirm genetic heterogeneity.
- Clinical data on osteogenesis imperfecta (OI) natural history and spinal deformities reported.
- Pilot studies on growth hormone therapy (for achondroplasia/hypochondroplasia) and nasal-osteocalcin (for OI) initiated.
- High complication rates associated with extensive limb lengthening noted.
- Enzyme replacement and gene transfer show potential for mucopolysaccharidoses.
Conclusions:
- Ongoing research is refining skeletal dysplasia classification and genetic understanding.
- Emerging therapies like growth hormone and enzyme replacement show potential but need long-term evaluation.
- Established treatments like limb lengthening remain controversial due to high complication rates.
Abstract:
Significant advances in the management of skeletal dysplasia have occurred during the past year. A revision of the Paris classification of constitutional disorders of bone has been proposed. New mutations have been identified in several disorders that confirm genetic heterogeneity within similar phenotypes. New clinical data of growth, fracture rates, and incidence of major skeletal and extraskeletal changes as well as the natural history and treatment of spinal deformities in osteogenesis imperfecta have been reported. Pilot studies of short-term growth hormone therapy in patients with achondroplasia and hypochondroplasia and nasal-osteocalcin therapy in osteogenesis imperfecta patients has been described, but the long-term effectiveness of these treatments remains to be determined. Extensive limb lengthening continues to be an important part of the treatment of patients of short stature in Europe, but complication rates continue to be very high. Both the current and future roles for this type of therapy are highly controversial. The potential for enzyme replacement therapy and retrovirus-mediated gene transfer in a variety of mucopolysaccharidosis disorders has been given new meaning by studies with cultured fibroblasts, which suggest that active enzymes can enter into and be synthesized in abnormal cells resulting in normalization of substrate turnover.